title: GPs have key role in shared care of patients with SLE.
abstract: The prevalence of systemic lupus erythematosus (SLE) is 28 per 100,000. The disease is most common in people of Caribbean or Asian descent. SLE mainly affects adults and is common in women between the ages of 20 and 40 years, with a female to male ratio of 9:1. The pathogenesis is multifactorial and encompasses multiple immunological, vascular and inflammatory processes. Diagnosing SLE can be challenging because of the myriad of clinical features and substantial variability between patients. Cutaneous involvement is present in about 60% of cases and typically manifests as a malar or butterfly rash. Joint involvement is inflammatory in nature with arthralgia, arthritis and/or tendinitis and occurs in about 90% of patients with SLE. Cardiorespiratory symptoms are common with chest pain on inspiration due to lupus-induced pleurisy or pericarditis, which may be associated with effusions. Lupus glomerulonephritis is one of the most important systemic complications, occurring in about 30% of patients with SLE in the UK. Careful screening tests for renal disease need to be undertaken as it is asymptomatic. The diagnosis of SLE is traditionally based on a combination of clinical features and laboratory findings and any patient with suspected clinical features of lupus should be investigated for the presence of autoantibodies. Treatment often includes corticosteroids, by various routes, at different points in disease management. In addition, some experts advocate the use of hydroxychloroquine, an antimalarial, as a principal drug in all SLE patients. It is beneficial in the management of mucocutaneous, musculoskeletal, serosal and constitutional symptoms.
authors.affiliation: SWBH NHS Trust, Birmingham.
authors.forename: Maame-Boatemaa
authors.initials: MB
authors.lastname: Amissah-Arthur
authors.forename: Caroline
authors.initials: C
authors.lastname: Gordon
mesh_terms: D005194:Family Practice; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis / Q000209:etiology; D008178:Lupus Erythematosus, Cutaneous / Q000175:diagnosis / Q000628:therapy; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D001523:Mental Disorders / Q000209:etiology / Q000628:therapy; D009422:Nervous System Diseases / Q000209:etiology / Q000628:therapy; D011379:Prognosis